Gudrun Würthwein1, Claudia Lanvers-Kaminsky1, Georg Hempel2, Silke Gastine2, Anja Möricke3, Martin Schrappe3, Mats O Karlsson4, Joachim Boos5. 1. Paediatric Haematology and Oncology, University Hospital Muenster, Albert-Schweitzer-Campus 1, Building A1, 48149, Muenster, Germany. 2. Department of Pharmaceutical and Medical Chemistry-Clinical Pharmacy, Corrensstraße 48, 48149, Muenster, Germany. 3. Department of Pediatrics, Christian-Albrechts-University Kiel and University Medical Center Schleswig-Holstein, Schwanenweg 20, 24105, Kiel, Germany. 4. Department of Pharmaceutical Biosciences, Uppsala University, P.O. Box 591, 75124, Uppsala, Sweden. 5. Paediatric Haematology and Oncology, University Hospital Muenster, Albert-Schweitzer-Campus 1, Building A1, 48149, Muenster, Germany. boosj@uni-muenster.de.
Abstract
BACKGROUND AND OBJECTIVES: The pharmacokinetics of the polyethylene glycol (PEG)-conjugated asparaginase Oncaspar® are characterized by an increase in elimination over time. The focus of our analysis is the better understanding of this time-dependency. METHODS: In paediatric acute lymphoblastic leukemia therapy (AIEOP-BFM ALL 2009), two administrations of Oncaspar® (2500 U/m2 intravenously) in induction phase (14-day interval) and one single administration in reinduction were followed by weekly monitoring of asparaginase activity. Non-linear mixed-effects modeling techniques (NONMEM) were used. Samples indicating immunological inactivation were excluded to describe the pharmacokinetics under standard conditions. Models with time-constant or time-varying clearance (CL) as well as transit compartment models with an increase in CL over a chain of compartments were investigated. RESULTS: Models with time-constant elimination could not adequately describe 6107 asparaginase activities from 1342 patients. Implementing a time-varying CL improved the fit. Modeling an increase of CL over time after dose (Emax- and Weibull-functions) were superior to models with an increase of CL over time after the first administration. However, a transit compartment model came out to be the best structural model. CONCLUSION: The increase in elimination of PEGylated asparaginase appears to be driven by physicochemical processes that are drug-related. The observed hydrolytically in vitro instability of the drug leads to the hypothesis that this increase in CL might be due to an in vivo hydrolysis of the instable ester bond between PEG and the enzyme combined with an increased elimination of the partly de-PEGylated enzyme (Trial registered at www.clinicaltrials.gov , NCT0111744).
BACKGROUND AND OBJECTIVES: The pharmacokinetics of the polyethylene glycol (PEG)-conjugated asparaginase Oncaspar® are characterized by an increase in elimination over time. The focus of our analysis is the better understanding of this time-dependency. METHODS: In paediatric acute lymphoblastic leukemia therapy (AIEOP-BFM ALL 2009), two administrations of Oncaspar® (2500 U/m2 intravenously) in induction phase (14-day interval) and one single administration in reinduction were followed by weekly monitoring of asparaginase activity. Non-linear mixed-effects modeling techniques (NONMEM) were used. Samples indicating immunological inactivation were excluded to describe the pharmacokinetics under standard conditions. Models with time-constant or time-varying clearance (CL) as well as transit compartment models with an increase in CL over a chain of compartments were investigated. RESULTS: Models with time-constant elimination could not adequately describe 6107 asparaginase activities from 1342 patients. Implementing a time-varying CL improved the fit. Modeling an increase of CL over time after dose (Emax- and Weibull-functions) were superior to models with an increase of CL over time after the first administration. However, a transit compartment model came out to be the best structural model. CONCLUSION: The increase in elimination of PEGylated asparaginase appears to be driven by physicochemical processes that are drug-related. The observed hydrolytically in vitro instability of the drug leads to the hypothesis that this increase in CL might be due to an in vivo hydrolysis of the instable ester bond between PEG and the enzyme combined with an increased elimination of the partly de-PEGylated enzyme (Trial registered at www.clinicaltrials.gov , NCT0111744).
Authors: M Hassan; U S Svensson; P Ljungman; B Björkstrand; H Olsson; M Bielenstein; M Abdel-Rehim; C Nilsson; M Johansson; M O Karlsson Journal: Br J Clin Pharmacol Date: 1999-11 Impact factor: 4.335
Authors: Stephan Borghorst; Rob Pieters; Hans-Juergen Kuehnel; Joachim Boos; Georg Hempel Journal: Pediatr Hematol Oncol Date: 2012-03 Impact factor: 1.969
Authors: Inge M van der Sluis; Lynda M Vrooman; Rob Pieters; Andre Baruchel; Gabriele Escherich; Nicholas Goulden; Veerle Mondelaers; Jose Sanchez de Toledo; Carmelo Rizzari; Lewis B Silverman; James A Whitlock Journal: Haematologica Date: 2016-03 Impact factor: 9.941
Authors: H J Müller; L Löning; A Horn; D Schwabe; M Gunkel; M Schrappe; V von Schütz; G Henze; J Casimiro da Palma; J Ritter; J P Pinheiro; M Winkelhorst; J Boos Journal: Br J Haematol Date: 2000-08 Impact factor: 6.998
Authors: Tong Lin; Todd Dumas; Josh Kaullen; N Seth Berry; Mi Rim Choi; Katie Zomorodi; Jeffrey A Silverman Journal: Clin Pharmacol Drug Dev Date: 2021-07-26
Authors: Ashley Nguyen; Diana S-L Chow; Lei Wu; Yang Angela Teng; Mahua Sarkar; Elizabeth G Toups; James S Harrop; Karl M Schmitt; Michele M Johnson; James D Guest; Bizhan Aarabi; Christopher I Shaffrey; Maxwell Boakye; Ralph F Frankowski; Michael G Fehlings; Robert G Grossman Journal: J Clin Pharmacol Date: 2021-07-09 Impact factor: 3.126
Authors: Christian Siebel; Claudia Lanvers-Kaminsky; Julia Alten; Petr Smisek; Christa E Nath; Carmelo Rizzari; Joachim Boos; Gudrun Würthwein Journal: Eur J Drug Metab Pharmacokinet Date: 2021-12-08 Impact factor: 2.441